EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium

Hans-Dieter Volk, Bernhard Banas, Frederike Bemelman, Oriol Bestard, Sophie Brouard, Cristina Cuturi, Josep M Grinyó, Maria Hernandez-Fuentes, Martina Koch, Björn Nashan, Irene Rebollo-Mesa, Alberto Sanchez-Fueyo und 5 weitere

Advances in Precision Medicine · 2016

DOI: 10.18063/apm.2016.01.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Precision Medicine, 2016. Verfasst von Hans-Dieter Volk und 16 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Solid organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure as it improves both quality of life and survival. Despite the progress in short-term graft survival, that is closely associated with the impressive reduction of acute rejections within the first year, long-term graft and patient survival remain almost un-changed and unsatisfactory. Incomplete control of chronic allograft injury but particularly the adverse effects of long-term immunosuppression, such as graft toxicity, diabetes, cardiovascular events, infections, and tumours continue to challenge the long-term success. In general, immunosuppression is applied as one-size-fits-all strategy. This can result in over- and under-immunosuppression of patients with low and high alloresponsiveness, respectively. Trial- and -error strategies to minimize or even completely wean of immunosuppression have a high failure rate. Consequently, there is an unmet medical need to develop biomarkers allowing objective risk stratification of transplant patients. To achieve this goal, we engaged in an academic-industrial partnership. The central focus of the European-wide BIO-DrIM consortium (BIOmarker-Driven IMmmunosuppression) is the implementation of biomarker-guided strategies for personalizing immunosuppression to improve the long-term outcome and to decrease the adverse effects and costs of chronic immunosuppression in solid organ transplant patients. The concept includes four innovative investigator-driven clinical trials designed by the consortium.

Zitieren

APA

Volk, H., Banas, B., Bemelman, F., Bestard, O., Brouard, S., Cuturi, C., Grinyó, J. M., Hernandez-Fuentes, M., Koch, M., Nashan, B., Rebollo-Mesa, I., Sanchez-Fueyo, A., Sawitzki, B., Berge, I. J. T., Viklicky, O., K, K. W., & Reinke, P. (2016). Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium. Advances in Precision Medicine. https://doi.org/10.18063/apm.2016.01.001

Vancouver

Volk H, Banas B, Bemelman F, Bestard O, Brouard S, Cuturi C, et al. Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium. Advances in Precision Medicine. 2016. doi:10.18063/apm.2016.01.001

BibTeX
@article{Volk2016,
  author = {Volk, Hans-Dieter and Banas, Bernhard and Bemelman, Frederike and Bestard, Oriol and Brouard, Sophie and Cuturi, Cristina and Grinyó, Josep M and Hernandez-Fuentes, Maria and Koch, Martina and Nashan, Björn and Rebollo-Mesa, Irene and Sanchez-Fueyo, Alberto and Sawitzki, Birgit and Berge, Ineke JM Ten and Viklicky, Ondrej and K, Kathryn Wood and Reinke, Petra},
  title = {Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium},
  journal = {Advances in Precision Medicine},
  year = {2016},
  doi = {10.18063/apm.2016.01.001}
}
Kostenlos starten →